Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

(2010) H. M. Kantarjian et al.   BLOOD

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

(2009) Paul W. Manley et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

(2009) C Tanaka et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Hypersensitivity reactions to cephalosporins

(2008) Esther Moreno et al.   Expert Opinion On Drug Safety

Chronic Myeloid Leukemia Stem Cells

(2008) Edward Kavalerchik et al.   JOURNAL OF CLINICAL ONCOLOGY

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

(2008) Oliver Hantschel et al.   LEUKEMIA & LYMPHOMA